6990 Stock Overview
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6990 from our risk checks.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$184.80 |
| 52 Week High | HK$223.80 |
| 52 Week Low | HK$115.00 |
| Beta | 0 |
| 11 Month Change | 2.21% |
| 3 Month Change | 12.68% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 57.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6990 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 5.3% | 2.4% | -1.5% |
| 1Y | n/a | -8.3% | 13.6% |
Return vs Industry: Insufficient data to determine how 6990 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 6990 performed against the Hong Kong Market.
Price Volatility
| 6990 volatility | |
|---|---|
| 6990 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6990 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6990's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,542 | Junyou Ge | kelun-biotech.com |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fundamentals Summary
| 6990 fundamental statistics | |
|---|---|
| Market cap | HK$41.18b |
| Earnings (TTM) | -HK$200.31m |
| Revenue (TTM) | HK$2.01b |
20.4x
P/S Ratio-205.6x
P/E RatioIs 6990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6990 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.88b |
| Cost of Revenue | CN¥713.66m |
| Gross Profit | CN¥1.16b |
| Other Expenses | CN¥1.35b |
| Earnings | -CN¥186.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 61.98% |
| Net Profit Margin | -9.94% |
| Debt/Equity Ratio | 0% |
How did 6990 perform over the long term?
See historical performance and comparison